ISA Pharmaceuticals BV

The rising demand for vaccine adjuvants is mainly due to the increasing rates of infectious and cancerous diseases. Other significant factors include the heightened need for vaccines for specific illnesses, a greater emphasis on immunization, and the expansion of vaccination programs globally. This trend is projected to persist through the forecast period from 2024 to 2030. LAS VEGAS, Aug. 29, 2024 /PRNewswire/ -- DelveInsight's Vaccine Adjuvants Market Insights report provides the current and forecast market analysis, individual leading vaccine adjuvants companies' market shares, challenges, vaccine adjuvants market drivers, barriers, trends, and key market vaccine adjuvants companies in the market. Key Takeaways from the Vaccine Adjuvants Market Report As per DelveInsight estimates, North America is anticipated to dominate the global vaccine adjuvants market during the forecast period. In the product segment of the vaccine adjuvants market, the oil-in-water emulsion category had a significant revenue share in the vaccine adjuvants Market in 2023. Notable vaccine adjuvants companies such as Dynavax Technologies, GSK plc, Croda International plc, SEPPIC, Novavax, SPI Pharma, Agenus Inc., Aurorium, Merck KGaA, Vaxine Pty Ltd., Hawaii Biotech Inc., CSL, OZ Biosciences, InvivoGen, Allergy Therapeutics, EUBIOLOGICS CO., LTD., Pacific GeneTech Limited, Riboxx GmbH, CaPtivate Pharmaceuticals LLC, Mukta Industries, and several others, are currently operating in the vaccine adjuvants market. In May 2023 Croda International Plc entered into a partnership with Amyris and Botanical Solutions Inc. firstly for biotechnology-derived squalene and secondly with BSI to develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than the traditional method of extracting QS-21 from soap bark trees. In August 2022, GSK Plc entered into an acquisition with Affinivax, Inc. to develop pneumococcal vaccines. To read more about the latest highlights related to the vaccine adjuvants market, get a snapshot of the key highlights entailed in the Global Vaccine Adjuvants Market Report Vaccine Adjuvants Overview Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the primary antigen. By stimulating the immune system more effectively, adjuvants can reduce the amount of antigen required and increase the duration of immunity. They play a crucial role in improving the efficacy of vaccines, particularly in cases where the antigen alone might not provoke a strong enough immune reaction. Adjuvants can work through various mechanisms, such as promoting a stronger local immune response at the injection site or facilitating a more robust activation of immune cells. Common types of adjuvants include aluminum salts, which have been used for decades and are known for their safety and effectiveness in boosting antibody responses. More recently, newer adjuvants like oil-in-water emulsions and toll-like receptor agonists have been developed to target specific aspects of the immune system. Research continues to explore and refine adjuvants to enhance vaccine performance, aiming to provide better protection against a range of infectious diseases and improve vaccine responses in different populations, including the elderly and immunocompromised individuals. Vaccine Adjuvants Market Insights In 2023, North America is anticipated to represent the largest share of the vaccine adjuvants market among all regions. This growth is driven by several factors. The region benefits from a well-established healthcare infrastructure and strong research and development capabilities, which stimulate advancements in vaccine adjuvant technologies. Additionally, increasing cases of infectious diseases and the threat of potential pandemics, like influenza or new pathogens, have led to greater investment in vaccine and adjuvant research. Government efforts to expand vaccination programs and enhance public health preparedness are also contributing to market growth. For example, the US Department of Health and Human Services (HHS) launched the HPV VAX NOW campaign in January 2021 to boost HPV vaccination rates among young adults. Similarly, the Government of Canada released updated guidelines on seasonal influenza vaccines for 2022-2023 in August 2022, which is expected to further stimulate market growth. Moreover, market expansion is supported by strategies such as product approvals, launches, and agreements. In November 2022, GSK plc's RSV vaccine candidate for older adults received a priority review from the FDA, indicating significant advancements in treatment or prevention. The combined effect of increased government and nonprofit investment in adjuvant development, alongside various product development activities, is set to drive the North American vaccine adjuvants market throughout the forecast period. To know more about why North America is leading the market growth in the vaccine adjuvants market, get a snapshot of the Vaccine Adjuvants Market Outlook Vaccine Adjuvants Market Dynamics The vaccine adjuvants market is experiencing significant growth driven by i ncreasing vaccine development and the demand for enhanced vaccine efficacy. Adjuvants are critical in improving the immune response to vaccines, which is particularly important as new and more complex pathogens emerge. The surge in research and development efforts, especially following the COVID-19 pandemic, has accelerated the need for innovative adjuvant technologies. Companies are focusing on developing adjuvants that can enhance the effectiveness of vaccines with lower doses, thereby addressing both efficacy and cost concerns. Technological advancements are playing a crucial role in shaping the dynamics of the adjuvants market. The development of novel adjuvants, such as nanoparticle-based and recombinant protein adjuvants, is gaining traction. These new technologies offer improved safety profiles and better control over immune responses. Additionally, the rise of personalized medicine and targeted therapies is driving interest in adjuvants that can be tailored to individual patient needs, further expanding the market potential. The r egulatory landscape and approval processes for vaccine adjuvants are also influencing market dynamics. Stringent regulatory requirements and the need for extensive clinical trials can pose challenges for market entry and innovation. However, successful navigation of these regulatory hurdles can lead to significant rewards, as demonstrated by the successful adjuvants used in COVID-19 vaccines. Companies that can efficiently meet regulatory standards while delivering effective solutions are likely to gain a competitive edge. Moreover, the vaccine adjuvants market is witnessing increased investment and collaboration between pharmaceutical companies, academic institutions, and government agencies. This collaborative approach is essential for advancing research, sharing knowledge, and accelerating the development of new adjuvant technologies. The convergence of resources and expertise from multiple stakeholders is expected to drive innovation and expand the market further. Overall, the vaccine adjuvants market is poised for substantial growth due to technological advancements, rising demand for effective vaccines, and increased investment in research and development. As the global focus on public health and disease prevention continues to intensify, the role of adjuvants in enhancing vaccine efficacy will remain a critical component of the healthcare landscape. Get a sneak peek at the vaccine adjuvants market dynamics @ Vaccine Adjuvants Market Dynamics Analysis Vaccine Adjuvants Market Assessment Vaccine Adjuvants Market Segmentation Vaccine Adjuvants Market Segmentation By Product Type: Oil-In-Water Emulsion, Aluminium Salts, Liposomes, Saponin-Based Adjuvants, and Others Vaccine Adjuvants Market Segmentation By Disease Type: Infectious Diseases, Cancer, and Others Vaccine Adjuvants Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the vaccine adjuvants market are set to emerge as the trendsetter explore @ Vaccine Adjuvants Companies Table of Contents Interested in knowing the vaccine adjuvants market by 2030? Click to get a snapshot of the Vaccine Adjuvants Market Trends Related Reports Vaccines Market Vaccines Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key vaccines companies, including GlaxoSmithKline, Bharat Biotech, AstraZeneca, Bavarian Nordic A/S, BioNTech, Sanofi, Merck & Co., Inc, Pfizer Inc, Moderna, Meiji Holdings Co., Ltd., EMERGENT, CSL Limited, Johnson & Johnson, VBI Vaccines Inc., Valneva SE., Novavax, CanSinoBIO, Biokangtai, Dynavax Technologies, Zhi Fei Biological, among others. Respiratory Syncytial Virus Market Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key RSV companies, including Bavarian Nordic, Pfizer, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, among others. Respiratory Syncytial Virus Pipeline Respiratory Syncytial Virus Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key respiratory syncytial virus companies, including GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, among others. Human Papillomavirus Market Human Papillomavirus Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HPV companies, including Inovio Pharmaceuticals, Inc., ISA Pharmaceuticals, Regeneron Pharmaceuticals, Barinthus Biotherapeutics, pHion Therapeutics, Vir Biotechnology, Inc., Antiva Biosciences, Toragen, Inc., Precigen, Inc, Merck Sharp & Dohme LLC, ViMREX GmbH, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

Around 5.2 million adults in the UK have moderate to severe atopic dermatitis. Image credit: Shutterstock / Kmpzzz. England’s National Institute for Health and Care Excellence ( Nice ) has recommended Almirall ’s Ebglyss (lebrikizumab) for patients with moderate to severe atopic dermatitis, giving NHS patients another biological therapy option. In line with NICE guidelines, the NHS will now have 90 days to make the treatment available to patients. Patients over 12 years of age who have not responded to or are not able to take systemic immunosuppressants will be eligible for the therapy, as per a 10 July press release. Monoclonal antibody Ebgylss will join Sanofi / Regeneron’s Dupixent (dupilumab) and Leo Pharma ’s Adbry (tralokinumab) as interleukin-targeting options for treating the skin condition. The Janus kinase (JAK) inhibitors Cibinqo (abrocitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) developed by Pfizer , Eli Lilly, and AbbVie , respectively, are also recommended by NICE. Atopic dermatitis, also known as atopic eczema, is an inflammatory skin condition characterised by intense itching. It has an estimated prevalence of up to 4.4% among adults in the EU. In the UK alone, around 5.2 million adults have moderate to severe atopic dermatitis. See Also: Dupixent “addresses current gap” in COPD biologics landscape Peltopepimut-s by ISA Pharmaceuticals for Cervical Cancer: Likelihood of Approval Ebglyss, which was approved in Europe in October 2023, and then two months later in the UK, works by inhibiting interleukin-13 (IL-13) signalling. IL-13 pathways play an important role in inflammation, driving the type-2 inflammatory loop in the skin. Adbry similarly targets IL-13 while Dupixent inhibits IL-13 and IL-4. The National Eczema Society’s chief executive Andrew Proctor said: “It’s important we have a range of treatment options, so patients have the chance to access a treatment that works well for them.” Almirall licensed the rights to develop and commercialise Ebglyss in dermatology indications, including atopic dermatitis, in Europe from Dermira in 2019. Dermira was then acquired by Eli Lilly, the latter retaining drug rights in the US and the rest of the world. Ebglyss is forecast to reach blockbuster status by 2026, according to GlobalData’s Pharma Intelligence Centre. By 2030, the drug is predicted to generate nearly $3.4bn in global sales. GlobalData is the parent company of Pharmaceutical Technology. Amid Sanofi and Regeneron’s Dupixent dominance , Johnson & Johnson (J&J) made a play for the atopic dermatitis space earlier this year when it spent $1.25bn to acquire Numab Therapeutics’ antibody NM26 in May.

The companies will focus on research for metabolic and infectious diseases. Credit: Orawan Pattarawimonchai/Shutterstock. Evotec and Pfizer have entered a multi-year partnership that will focus initially on early discovery research. As part of the master research collaboration and option and licence agreement, the two companies will focus on research for metabolic and infectious diseases. Evotec plans to undertake research activities at its facilities in France, including the advanced Campus Curie research site in Toulouse. The site is equipped with high throughput screening capacity, in vitro and in vivo biology, metabolomics and proteomics. Evotec chief business officer Dr Matthias Evers stated: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. See Also: Dupixent “addresses current gap” in COPD biologics landscape Peltopepimut-s by ISA Pharmaceuticals for Cervical Cancer: Likelihood of Approval “Focusing on diseases with severe unmet medical needs and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D [research and development] activities.” Evotec will benefit from research support funding from Pfizer and may receive potential milestones and royalty payments contingent on the success of the programmes. Pfizer France vice-president and medical lead Dr Luca Mollo stated: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. “France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need.” In April 2024, Evotec and Variant Bio teamed up to detect a treatment for ailments caused by fibrosis. The alliance will combine Variant Bio’s genomic discovery expertise and its VB-Inference platform with Evotec’s antifibrotic drug discovery capabilities.